Investigation of the Cu2S − CoS – TiS2 System at 870 K.

870 K. У цій системі виявлено нові тернарний та тетрарний сульфіди, що кристалізуються в кубічній сингонії: просторовій групі Fd-3m, стр. типі MgAl2O4 з параметрами елементарної комірки для Cu2CoTi3S8 – а = 0,99003 нм і для Cu2Ti4S9 – а = 1,00034 нм, утворюючи між собою необмежений ряд твердих розчинів. Ключові слова: халькогеніди, ізотермічний переріз, кристалічна структура, рентгенівська дифракція. Isothermal section of the Cu2S – CoS – TiS2 system at 870 K was investigated by X-ray phase analysis results. A new ternary and a quaternary sulfide were discovered in this system. They both crystallize in the cubic symmetry, space group Fd-3m, MgAl2O4 structure type, with the unit cell parameters а = 0,99003 nm for Cu2CoTi3S8 and а = 1,00034 nm for Cu2Ti4S9. The compounds form a continuous solid solution series. Key words: chalcogenides; isothermal section; crystal structure; X-ray powder diffraction

The Theoretical Description for Chlorantraniliprole Electrochemical Determination, Assisted by Squaraine Dye – Nano-CuS Composite

The theoretical description for the chlorantraniliprole electrochemical determination, assisted by the hybrid composite of squaraine dye with CuS nanoparticles has been described. The correspondent reaction mechanism has been proposed, and the correspondent mathematical model has been developed and analyzed by means of linear stability theory and bifurcation analysis. It has been shown that the chlorantraniprole electrochemical anodical determination on high potential may be efficiently provided by cupper sulfide nanoparticles, stabilized by the squaraine dye. On the other hand, the oscillatory and monotonic instability is also possible, being caused by DEL influences of the electrochemical stage. DOI: http://dx.doi.org/10.17807/orbital.v13i3.151

Theoretical Description for Omeprazole Cathodical Electrochemical Determination, Assisted by Omeprazole Electrochemical Determination, Assisted by the Composite Poly(1,2,4-triazole) – VO(OH)

Abstract: In this work, we describe theoretically the possibility of omeprazole electrochemical determination, assisted by the composite containing vanadium oxyhydroxide as an active substance and the polymer of 1,2,4-triazolic derivative as a mediator. The omeprazole molecule undergoes a sulfoxide to sulfide reduction process over a trivalent vanadium compound. The vanadium oxyhydroxide, at its turn, may be oxidized to a tetravalent state, represented in two forms. The electroanalytical process behavior will be illustrated by a trivariate equation-set, analysis of which confirms the efficiency of the composite of poly (1,2,4-triazole) with VO(OH). Vanadium (III) oxyhydroxide may be efficiently used for omeprazole detection both in pharmaceutical formulations, food, and biological liquids

Evolution of СD95+-cells in peripheral blood of patients with ovarian cancer in during the combined treatment

Paper deals with the content of CD95+-cells in the blood of patients with ovarian cancer and benign tumors. Found that patients with a malignant process and low CD95+-cells before treatment and during chemotherapy have a poor survival. The initial increase in the relative level CD95+- cells has no effect on survival, increasing the relative level CD95+-cells during chemotherapy is associated with poor survival. Concluded that the CD95 can not be a factor in the forecast, but the reaction of the organism to maintain its level within the physiological range in the treatment of ovarian cancer patients can achieve significantly better long-term results

Management and results of treatment of patients with refractory ovarian cancerr

The results of observation of 22 patients with refractory ovarian cancer were analyzed. The usefulness of chemotherapy the second and  subsequent lines of treatment is shown. Sequential treatment by not cross-resistant chemotherapy allows increase median survival up  to 12.5 months in general group. In 36 % of patients with good performance status prolonged stabilization of disease with median overall survival of 22.3 months was achieved

MANAGEMENT IN EARLY OVARIAN CANCER: STANDARDS AND UNSOLVED PROBLEMS

The appropriate management of early-stage ovarian carcinoma is controversial. The literature has been analyzed to find answers to the following questions: how to make an early diagnosis of ovarian cancer and to minimize the treatment in order to avoid complica- tions and toxicity without any harm to health and to increase therapeutic effectiveness. The use of the current noninvasive techniques (positron emission tomography, magnetic resonance imaging) is shown to considerably improve the diagnostic estimation of the extent of a tumor. This fact and deeper knowledge of prognostic factors will allow us to optimize and individualize treatment

Optimal cytoreduction for advanced epithelial ovarian cancer

This article is review of literature on role of surgery in the initial management of advanced stage ovarian cancer, focusing on the definition of optimum surgical cytoreduction, assessment of resectability, estimation of the risk of postoperative complications. Analyze of published scien- tific data suggest that removal of all evidence of macroscopic disease should be the goal of primary or interval cytoreductive surgery

Optimal cytoreductive surgery in patients with disseminated ovarian cancer (the department’s experience)

One hundred and one patients with disseminated ovarian cancer (OC) treated at Surgery Department Eight, Research Institute of Clinical Oncology, N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, in 1998–2007 and continued to be followed up and treated till March 2012 were examined to make a clinical analysis of the course of the disease. Median follow-up was 32 months. The proportion of patients with Stages III–IV OC was 87 %. Optimal cytoreductive surgery was shown to be possible in 21 (20.8 %) patients dur- ing Stage 1 combination therapy and in 20 (19.8 %) patients after neoadjuvant chemotherapy (CT). The maximum survival rates (with a median of 87.7 months) were achieved in 21 patients who had undergone optimal surgery and had a tumor that is highly susceptible to CT with platinum derivatives. It is concluded that it is necessary to improve the diagnosis of the disease for increasing treatment results

Refractory mixed peritoneal adenocarcinoma arising from the foci of external endometriosis: a clinical note

The paper describes a case of mixed (clear cell and endometrioid) peritoneal adenocarcinoma developing in a patient 12 years after surgical treatment for genital endometriosis

Platinum preparations in the treatment of trophoblastic tumors

The N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, has developed and used new polychemotherapy regimens including platinum preparations for the treatment of patients with trophoblastic tumors. A cysplatin + ethoposide or carboplatin + ethoposide (CyE/CaE) combination was used as second-line chemotherapy in methotrexate-resistant locally advanced form (Stages I-II) of the disease. A cysplatin or carboplatin + methotrexate + dactinomycin + vincristine) (CyMDV/CaMDV) regimen was used as first-line therapy in patients with disseminated (Stage III-IV) disease and as second-line therapy in patients with its resistant form (Stages III-IV). The CyE/CaE regimen could cure 21 patients with Stages I-II without surgical intervention. When the CyMDV/CaMDV regimen was used as first-line therapy in 24 patients with Stages III-IV disease, of them 21 (87.5%) patients achieved a complete therapeutic effect, they all have been survivors to the present time. The CyMDV/CaMDV regimen used as second-line chemotherapy in patients with the resistant form turned out to be effective in 5 (83.3%) of 6 cases. The follow-up lasted > 3 years.The benefit of the developed regimens including platinum preparations is that they are effective, less toxic, require long hospitalization and are technically simpler, which allows them to be used in the outpatient setting of the wide oncological network